drugset
drugset / Trial / NCT03536325

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

NCT03536325 ↗

Phase 1 Completed 24 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to assess the safety and tolerability of guselkumab following single-dose intravenous (IV) infusion in Japanese healthy male participants.

Timeline

Start
2018-05-31
Primary completion
2018-10-25
Completion
2018-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody — Intravenous

Indications

No indication recorded.